Abstract

Purpose: Treatment results evaluation (radical cystectomy and adjuvant chemo/radiotherapy) in patients with urothelial carcinoma, squamous differentiation carcinoma and pure squamous bladder carcinoma.

Material and methods: The study included 361 patients with invasive bladder carcinoma treated between 1990-2013. Histology showed 296 cases of urothelial carcinoma (82% – group A), 52 cases of urothelial divergent differentiation (squamous and urothelial carcinoma 14.4% – group B) and 13 cases of squamous cell carcinoma (3.6% – group C). All patients benefited from radical cystectomy. Adjuvant chemotherapy was undergone in 68 patients.

Results: Group A – urothelial carcinoma – had a 44% rate of patients alive with a mean survival period of 73 months. About 56% of the patients died, the mean survival period being 4 years.

Group B – urothelial carcinoma with squamous differentiation – had a mean survival period of 36 months (between 1-156 months). 17 patients (33%) are alive at 50 months postoperatively.

Group C – squamous carcinoma – had a mean survival period of 9.4 months.

Discussions: Locally advanced disease was diagnosed in 50% of the patients in group A, while in group B the rate was 84.6% and 70% in group C, respectively.

Conclusions: Squamous pattern detected in the histopathological specimen represents a negative prognostic factor. It seems that the squamous component influences the outcome of the disease due to its biological characteristics in the evolution of squamous carcinoma, with advanced local stage disease at diagnosis – late onset of symptoms and lack of response to adjuvant treatment.

Abbreviations: SCC = squamous cell carcinoma; MSK = Memorial Sloan Ketering